Blackstone backs biopharma business Alnylam with up to $2bn
Tue, April 14, 2020AltAssets
Blackstone has agreed to provide biopharma business Alnylam Pharmaceuticals with up to $2bn to support the company’s development of medicines targeting patients suffering from debilitating diseases.